Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Updates in the Pathophysiology of Itch
Description
The presentation discusses recent advancements in understanding the pathophysiology of itch, particularly in relation to conditions like urticaria and atopic dermatitis. Initially, it highlights the historical role of histamine in causing itch but points out that newer research has uncovered various other neuronal and molecular mechanisms that contribute to the sensation of itch. Key advances include the identification of specific receptors on peripheral neurons, such as MRGPRS and the role of cytokines like IL-4 and IL-13 in mediating itch responses. The speaker emphasizes the neuroimmune interface where itch can also influence inflammatory responses, suggesting a bidirectional relationship between itch and inflammation. They also touch on the varied nature of itch, distinguishing between inflammatory and neurogenic types, and discuss the implications for drug development, noting the efficacy of therapies targeting these pathways—such as monoclonal antibodies and JAK inhibitors—in providing relief for patients with chronic itch conditions. The discussion incorporates recent findings on IL-33’s role in modulating itch and highlights ongoing research into how chronic inflammatory conditions shape mast cell behavior and alter the itching response. Overall, the session underscores the complexity of itch physiology and the importance of understanding these mechanisms for developing targeted therapies.
View moreConclusions
- There is a growing understanding of the mechanisms involved in itch, particularly through the role of various cytokines and neuropeptides.
- Itch can be classified into inflammatory and neurogenic types, emphasizing the complexity of itch pathways.
- Histamine is known to play a significant role in itch, but many itch mechanisms are non-histaminergic and involve mast cell mediators.
- Cytokines such as IL-33 and IL-13 have been shown to amplify the sensation of itch, particularly in conditions like chronic spontaneous urticaria.
- Mast cells are identified as prevalent expressers of IL-33R, linking them to itch in various conditions.
- Blocking pathways involving IL-33 and targeting specific receptors can be effective for managing chronic itch.
- There is evidence that basophils may play a unique role in mediating acute itch, especially in atopic dermatitis and other inflammatory conditions.
- Understanding the interplay between mast cells and neural pathways can inform therapeutic strategies for itch.
- Research indicates that therapies targeting JAK inhibitors and IL-31 may provide rapid relief from itch in clinical settings.
- Mu et al. Science 2017
- Mishra et al. Cell 2013
- Sun and Chen Nature 2007
- Liu et al. Cell 2009
- Han et al. Nat Neuro 2013
- Kim et al. Sci Transl Med 2013
- Oetjen et al. Cell 2017
- Kim et al. J Immunol 2014
- Nguyen et al. eLife 2021
- Yosipovitch et al. Nat Med 2023
- Wang et al. Cell 2021
- Auyeung et al. Ann Allergy Asthma Immunol 2023
- Trier and Ver Heul JACI 2023
- GSE57178
- GSE72540
- GSE96695